

efw

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT (Under 37 CFR 1.97(b) or 1.97(c))					Docket No. PN0384	
In Re Application Of: Alan Cuthbertson, et al.						
Application No. 10/559,880	Filing Date To be assigned	Examiner To be assigned	Customer No. 36335	Group Art Unit To be assigned	Confirmation No. 2898	
Title: Contrast Agent						
Address to: Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450						
37 CFR 1.97(b)						
1. <input checked="" type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.						
37 CFR 1.97(c)						
2. <input type="checkbox"/> The Information Disclosure Statement submitted herewith is being filed after the period specified in 37 CFR 1.97(b), provided that the Information Disclosure Statement is filed before the mailing date of a Final Action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an Action that otherwise closes prosecution in the application, and is accompanied by one of:						
<input type="checkbox"/> the statement specified in 37 CFR 1.97(e);						
OR						
<input type="checkbox"/> the fee set forth in 37 CFR 1.17(p).						

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

(Under 37 CFR 1.97(b) or 1.97(e))

Docket No.

PN0384

In Re Application: Alan Cuthbertson, et al.

JUL 24 2006

Application No.

Filing Date

Examiner

Customer No.

Group Art Unit

Confirmation No.

10/559,880

To be assigned

To be assigned

36335

To be assigned

2898

Title: Contrast Agent

Payment of Fee

(Only complete if Applicant elects to pay the fee set forth in 37 CFR 1.17(p))

- ☐ A check in the amount of _____ is attached.
- ☐ The Director is hereby authorized to charge and credit Deposit Account No. _____ as described below.
- ☐ Charge the amount of _____
- ☐ Credit any overpayment.
- ☐ Charge any additional fee required.
- ☐ Payment by credit card. Form PTO-2038 is attached.

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Certificate of Transmission by Facsimile*

I certify that this document and authorization to charge deposit account is being facsimile transmitted to the United States Patent and Trademark Office (Fax. No. _____)

(Date)

Signature

Typed or Printed Name of Person Signing Certificate

Certificate of Mailing by First Class Mail

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on _____

(Date)

Signature of Person Mailing Correspondence

Lori Allaire

Typed or Printed Name of Person Mailing Certificate

*This certificate may only be used if paying by deposit account.

Signature

Dated:

July 20, 2006

Li Cai
Reg. No. 45,629
GE Healthcare, Inc.
101 Carnegie Center
Princeton, NJ 08540
(609) 514-6418

CC:

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEATTY. DOCKET NO.
PN0384SERIAL NO.
10/559,880INFORMATION DISCLOSURE
STATEMENT BY APPLICANTAPPLICANT
Alan CuthbertsonFILING DATE
12/07/05GROUP
To be assigned

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,444,069	08-1995	Dudley, et.al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	98/18496	05-1998	WO				
	2004/062568	07-2004	WO				
	2005/030266	04-2005	WO				
	03/006070	01-2003	WO				
	03/051859	06-2003	WO				
	03/006491	01-2003	WO				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER INITIAL	
	Ponchant, M. et.al. "Radiosynthesis of [tetrazoyl-11C]irbesartan, a non-peptidic angiotensin II antagonist" European Journal of Medicinal Chemistry Editions Scientifique Elsevier, Paris Fr., vol. 32, no. 9, Sept. 1997, pages 747-752
	Burns, H.D., et.al. "Development of of [11C]L-159,884: A Radiolabelled, Nonpeptide Angiotensin II Antagonist that is Useful for Angiotensin II, At1 Receptor Imaging" Applied Radiation and Isotopes, Pergamon Press Ltd., Exeter, GB, vol. 47, no. 2, Feb. 1996, pages 211-218
	Int'l Search Report and written opinion PCT/NO2004/000358 dated Nov-2005

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not conformance and not considered. Include copy of this form with next communication to applicant.